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Summary.-A Phase I study of oral daily misonidazole (MISO) with conventional
pelvic irradiation, has been conducted in patients with carcinoma of the cervix
Stages IB, IIB, IIIB and IVA. MISO was administered in daily dosages to sequential
groups of patients at doses of 0*15 g/m2, 0-30 g/m2 or 0-45 g/m2 for 22 days over 5
weeks. Sixteen patients were assigned to each dose level. Using a double-blind
randomization, they received either placebo (3/16) or MISO (13/16). The major dose-
limiting toxicity was peripheral neuropathy (PN). None of the 13 patients receiving
0.15 g/m2 or the 13 receiving 03 g/m2 developed PN. However, 6/13 at the 0-45 g/m2
level (total dose 9.9 g/m2) developed PN. Additional patients were entered at this
level and a total of 13/26 developed PN, which was considered of clinically significant
severity in 9. Symptoms of PN have persisted from 1 week to 10 months, and have
been completely reversed in 9/13 patients. Pharmacological parameters were exam-
ined for correlation with clinically evident toxicities. Although peak plasma MISO
levels and half-lives did not correlate significantly with PN, there was a significant
correlation between the calculated "area under the curve" (AUC) and PN. No corre-
lation exists between PN and total urinary excretion of MISO or the 0-demethylation
product. A daily dose of 0*45 g/m2; MISO (total dose <99 g/m2) is considered to
produce an acceptable level of toxicity for this patient population.
SINCE MISONIDAZOLE (MISO) has been
shown to have efficacy experimentally as
an hypoxic cell radiation sensitizer, inter-
est has grown in its use in the treatment of
patients with carcinoma (Dische et al.,
1978b; Bleehen, 1980; Kogelnik, 1980;
Wasserman et al., 1981; Sealy, 1978).
The patient groups in which the addi-
tion of MISO may improve the clinical
results are those in which local control
due to the presence of hypoxic cells is a
problem, and conventional radiation doses
cannot be effectively increased because of
the limiting tolerance of the surrounding
normal tissues.
The conventional method of examining
a new therapeutic agent is to conduct a
Phase I (toxicity) study to establish the
optimal dose and method of administer-
ing the agent. Because optimal scheduling
ofthe combination ofMISO and radiation
is unknown, initial Phase I trials have
examined many dose schedules (Dische
et al., 1978a; Wasserman et al., 1981)
ranging from weekly to daily drug doses,
in combination with diverse radiation
schedules. The observed dose-limiting
toxicity in all these studies has been
neurotoxicity, and although the develop-
ment of this toxicity appears to be related
primarily to the total MISO dose, it may
also be dependent on the drug schedule.
Another factor which may be important
in determining an individual's suscepti-
bility to MISO neuropathy is the pre-
treatment neurological status of patients
in whom it is used. Some of the neuro-
toxicity data in the literature has beenMISO AND IRRADIATION FOR CARCINOMA OF CERVIX
generated from the administration of
MISO to patients with pre-existing neuro-
logical abnormalities (Wasserman et al.,
1979) and such data may not be applicable
to patient groups without such abnormal-
ities. It is also difficult to interpret the
reported severity ofneurotoxicity without
specified criteria for the grading systems
used to quantitate it (Wasserman et al.,
1981). At present, although the grading
systems used for quantitating neuro-
toxicity (Wasserman et al., 1981) may be
internally consistent for one group of
observers, it is impossible for others to
appreciate the severity of a subjective
complaint such as paraesthesias when
specified criteria are not defined to des-
cribe terms such as "mild", "moderate"
and "severe".
We felt it was important therefore to
carry out our own Phase I trial, establish-
ing specific toxicity data for a given MISO
and radiation schedule in a pre-defined
patient population, for its planned use in
formal Phase III trials in a similarly
defined population. Patients with car-
cinoma of the cervix were considered a
suitable patient population for the investi-
gation of the use of MISO with radiation,
since there is indirect evidence of hypoxic
cells in these tumours (Bush et al., 1978),
and local control is incomplete with
radiation particularly with advanced tum-
our stages. The stages of disease chosen
for this study were those in which failure
within the radiation field accounts for
50 to 75% ofdeaths from disease (Princess
MargaretHospitaldata, Bushetal., unpub-
lished). Conventional radiation alone pro-
duces a measurable cure rate in patients
with carcinoma ofthe cervix (Bush, 1978).
If present control rates with radiation lie
on the steep part of the sigmoid dose-
control curve, the expected small benefits
from the addition of MISO (Dische et al.,
1978b) could result in substantial improve-
ments in local control.
Unlike most Phase Istudies, thepatients
chosen for this study were not those in
whom most other conventional therapies
had failed to eradicate the tumour. The
conservative design of this study using
established conventional daily radiation
fractionation and starting with extremely
low total doses of MISO, reflect a concern
that existing cure rates for potentially
curable patients were not compromised
and that the therapeutic ratio would not
be negated by the toxicity of excessive
doses ofMISO.
MATERIALS AND METHODS
From May 1979 to May 1981 64 patients
with carcinoma of the cervix FIGO Stages
IB (>5 cm diameter), IIB, III and IVA
were entered into this toxicity study. The
criteria for eligibility are similar to those
used in our previous parallel Phase I study
of metronidazole and pelvic radiation
(Thomas et al., 1980).
Patients were treated with our standard
megavoltage external pelvic irradiation: a
tumour dose of45 Gy in 20 fractions (5/week)
Intracavitary caesium (137Cs) usually fol-
lowed external therapy using one application
of a linear source without colpostats (vaginal
applicators) to deliver a dose of 40 Gy at
2 cm from the centre ofthe sources.
The patients were randomized (double-
blind) to receiveMISO (supplied byHoffman-
La Roche Limited, Vaudreuil, Quebec,
Canada) or placebo capsules orally 4 h before
each fraction ofexternal irradiation (20 days)
and once daily during the application of
intracavitary radiation (137Cs) for a total of
22 treatment days. The scheme for random-
ization and allocation of patients to receive
MISO or placebo is shown in Table I. The
study was designed to assess 16 patients
sequentially at each of 4 daily MISO dose
levels: 0-15, 0 3, 0 45 and 0-6 g/m2 (total
doses of 3.3, 6-6, 9.9 and 13-2 g/m2). The dose
levels selected ranged from levels at which
no neurotoxicity had been reported by other
investigators (3-3 g/m2 total) to a planned
maximum (13-2 g/m2) considered to be in the
acceptable dose range by other investigators
(Dische et at., 1978a; Wasserman et al., 1980).
At each dose level 13 patients were random-
ized to receive MISO and 3 to receive placebo
capsules. Patient accrual to each dose level
was completed and evaluated before progres-
sing to the next level. Observations on
patients at the 0 45 g/m2 dose level led to a
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modification of the original study design. A
further 16 patients were entered at this level
and none were entered at the 0-6 g/m2 level.
Drug administration was discontinued if
neurotoxicity developed or any other toxicity
intolerable for the patient.
Clinical assessments were performed before
treatment, at least weekly during treatment,
and after treatment wNas completed at twNo-
wveekly intervals for 1 month, at monthly
intervals for 3 months and finally at 6 months
and 1 year. Assessments were more frequent
if neurological abnormalities developed, and
were continued until all abnormalities dis-
appeared. Specific attention was paid to
symptoms of acute gastrointestinal toxicity,
and the severity of these symptoms were
measured on toxicity scales previously estab-
lished in our metronidazole study (Thomas et
al., 1980). Detailed neurological examinations
were performed on all patients. Pretreatment
nerve-conduction studies were not routine,
but were done if neurological abnormalities
were detected or suspected on the basis of
patient symptoms or objective findings on
examination. Audiograms,were performed on
25 of the 26 patients receiving 0 45g/m2
MISO daily, before and at the completion of
treatment.
The observed acute toxicities were com-
pared to those of our previous study of a
similar patient population receiving metro-
nidazole with radiation (Thomas et al., 1980)
as well as between patients receiving placebo
capsules and those receiving MISO.
Baseline and weekly haematology tests
were obtained on all patients. All patients
were admitted to hospital on the first treat-
ment day, and on the last day (Day 20) of
external therapy if they completed the pre-
scribed course of capsules plus radiation.
While in hospital, 24 h serial blood sampling
(15 samples) via an indwelling venous
catheter, yielded plasma for high-pressure
liquid chromatography (HPLC) assay of
MISO and desmethyl MISO levels (Workman
et al., 1978). Twenty-four hour urine samples
were also collected for HPLC determinations
of drug and metabolite levels. The HPLC
data were used to calculate the pharmaco-
kinetic parameters: plasma half-life, peak
plasma levels and exposure-time or "area
under the curve" (AUC). These pharmaco-
kinetic parameters were examined for cor-
relation with any of the clinically observed
toxicities.
RESULTS
Clinical
The administration of MISO did not
interfere with the planned course of
radiation. In spite of the development of
drug-related toxicity (described below) all
patients completed pelvic irradiation with-
out interruption.
According to their own daily record of
capsule administration, all patients took
over 90% of the total prescribed cap-
sules, unless they were discontinued by
the physician. Random weekly HPLC
determination ofplasma MISO levels con-
firmed the presence of appropriate drug
levels in patients taking MISO capsules,
thus confirming patient compliance. MISO
was discontinued during the planned
course of administration because of the
development of toxicity in 0/13, 1/13 and
7/26 patients at the 0 15, 0 30 and 0 45g/
m2 daily dose levels, respectively. Five
patients developed anerythematous macu-
lar pruritic rash, possibly attributable to
MISO (Partington et al., 1979) after total
doses of 0-6-1 0 5 g. In 4 of the 5 the rash
was not severe enough to warrant cessa-
tion of MISO administration, but in the
fifth patient a pruritic rash appeared on
the palms of the hands and soles of the
feet. A nerve-conduction study at the
time of onset of the rash was abnormal,
necessitating cessation of MISO adminis-
tration. In all 5 patients the rash subsided
spontaneously within I week, even when
MISO was continued.
Gastrointestinal toxicity (specifically
nausea and vomiting) was a significant
problem for only one patient receiving
MISO. She declined further drug after
16 days at 03 g/m2/day, a total of 6 4 g.
No exacerbation of radiation-induced
diarrhoea was observed in the patients
receiving MISO at any dose level.
One of 52 patients receiving MISO +
irradiation and 1/12 receiving placebo +
irradiation developed significant suppres-
sion of peripheral platelet counts
( < 150,000/mm3) during treatment. Two
patients receiving MISO and 2 receiving
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placebo showed suppression of peripheral
WBC counts to 3 0 x 103/mm3. These
effects were detected ontheroutine weekly
haematological tests, and did not produce
any episodes of spontaneous bleeding or
sepsis.
Neurological toxicity
There was no evidence for the develop-
ment of clinically significant hearing
abnormalities in any ofthe patients receiv-
ing MISO. No patient complained of
decreased hearing or tinnitus, but of the
25 patients taking 045 g/m2 daily MISO
who had pre- and post-treatment audio-
grams, 4 developed transient audiological
abnormalities (Table III) consisting of a
15-40 decibel hearing loss in the high-
frequency range, usually at 8000 Hz. All
4 of these patients developed other
neurotoxicity. No patient at any dose
level developed clinically recognizable
CNS toxicity.
Peripheral neuropathy (PN) did not
develop in any of the MISO-treated
patients at the 0415 or 0-3 g/m2 dose levels
(Table I). One of the 16 patients at the
0-3 g/m2 level developed symptoms of
peripheral sensory neuropathy confined to
the toes of both feet, but when the ran-
domization code was broken it showedthat
she had been receiving placebo capsules.
TABLE II.-Peripheral neuropathy (PN)
severity scale
Grade Definition
1 "Minimal". Occasional or intermittent
symptoms, elicited on questioning.
2 "Moderate". Constant symptoms
volunteered by patients, worse than
Grade 1 but not interfering with activity
and not requiring analgesics.
3 "Severe". Constant symptoms interfering
with walking, working or sleeping, or
requiring analgesics.
hands were also involved. Symptoms
varied in character, severity and frequency
patients described constant or inter-
mittent sensations of pain, burning, tight-
ness, numbness, paraesthesias, sharp
shock-like sensations orhyperaesthesia. On
this basis (Table II), the 13 developing PN
at 0 45 g/m2, was classified as Grade 1 in
4/13 patients, Grade 2 in 4/13 patients and
Grade 3 in 5/13 patients (Table III).
TABLE III.-Clinical characteristics
Neurotoxicity
Severity
grade Total
1
2
3
4
4
5
No. of patients
With
With abnormal With
objective nerve abnorrn
signs conduction audiogr
2 1 2
3
4 4
0
2
of
nal
,am
TABLE I.-Study design and incidence of
neuropathy by drug dose
Daily
MISO
dose
(g/m2)
0-15
0 30
0 45
0-60
No. of
drug
days
22
22
22
22
Total
dose No. of Patients
(g/m2) MISO Placebo
3 -3 13
6-6 13
9 9 13
13 - 2 13
3
3
3
3
Incidence of
neuropathy
in MISO
treated
0/13
0/13
13/26
ND
At the 0 45 g/m2 dose level, 13/26
MISO patients developed PN compared
with 0/6 patients receiving placebo (Table
I). The symptoms in all patients were
those of a peripheral sensory polyneuro-
pathy. No patient developed symptoms
of motor impairment. All 13 patients with
PN had symptoms in the feet; in 6 the
Objective signs accompanied the sen-
sory symptoms in 9/13 patients with PN
(Table III). Sensory impairment to pin
prick in the feet was the most common
objective finding, and this extended up to
the knee and mid thigh in 2 patients with
Grade 3 PN. Sensory impairment to light
touch, vibration and temperature was
also noted in 3/5 patients with Grade 3,
and 1/4 with Grade 2 PN.
Nerve-conduction studies performed
after PN was clinically recognized did not
always correlate with the severity of the
symptoms of PN. Abnormalities were
detected in 6 of the 13 patients with PN
in whom they were performed (Table III).
The changes were characteristic of a distal
axonal rather than a primary demyelinat-
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ing neuropathy. They were usually mini-
mal in severity, showing a decreased
amplitude in the sural nerve response,
though in 2 patients sensory-nerve con-
duction was absent in the lower extremi-
ties. In 3 patients there was evidence of
motorabnormality, with slight diminution
in the motor evoked response or mild
denervation of the small muscles of the
feet. Those with motor abnormalities in
nerve-conduction studies all had a PN
severity ofGrade 3.
The time of onset of PN varied. ln 7/13
patients, PN became evident during treat-
ment. The earliest appearance was on the
12th day of MISO administration. In 6/13
patients, PN started 2-10 days after
completion of treatment. In the majority,
the peak in severity of the symptoms of
PN arose rapidly in the first week after
onset, persisted at the peak level for 6
weeks to 2 months and gradually subsided
se of PN due to MIISO.
TABLE IV.-Pharmacokinetics of 11ISO
Day I
Dose level
(g/m2) n
0.15 13
0.30 13
0*45 26
Day 20
0*15
0 30
0 45
13
12
20
1'eak level AUC
T; (Ii)
7-7+ 1-8
9*1 + 2 - 6
9'0+ 2-0
9-5+2- 6
10*1 + 2 I
10- 0+2-8
( MM)
35+8
70+ 12
98 + 22
40+6
90 + 14
116 + 26
(1AM. h)
345+56
747+ 132
1035 + 280
486 + 108
979 + 280
1250+ 260
(Figure). The persistence of PN was also
variable. To date PN has resolved in 9/13
patients after 1 week to 10 months (mean
3*3 months). In 4/13 PN is unresolved and
has persisted for 2-9 months (Figure).
Pharmacokinetics
Table IV shows the means + s.d. of
pharmacokinetic parameters for all
patients at the 3 MISO dose levels: MISO
half-life (T1/2), MISO peak plasma levels
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and total exposures (AUC) as measured
from serial plasma and urine samples
obtained on the 1st and 20th day of MISO
administration. No large changes were
found between parameters measured on
the samples taken on the 20th day of
treatment and those on the 1st day. The
slightly raised peak and AUC on Day 20
is probably due to residual MISO (- 25%,)
in the plasma from the 19th-day dose.
There was no other evidence of accumula-
tion of drug over the 20 days of MISO
administration. There was a tendency for
the mean T1/2 to increase from initial to
Day 20 kinetics, but this was within the
standard deviation of the 2 measure-
ments.
TABLE V. Comparison ofpharrnacokinetic
parameters for patients with and woithout
peripheral neuropathy at 0 45 g/m2 daily
Parameter
TI/2 (1)
Pleak (foi)
Time to peak (hi)
I )esmethyl/AIS()
(Plasma)
AUC (ZoI II)
D)ays x AUC I 8
o°, AIIS() (lose inI
uirine
I )esmethyl/I1S()
(uIrIine)
Table V shows
of the pharmacoki
patients developing
niot, at the 0 45 g/n
mean T1/2 of the g
PN is longer and th
than those of pati
Values fall within t
of the two measurer
the 26 patients at
are ranked accor
(Table VI) the
(Campbell, 1979) in
distribution for pat
from that of patien
5% confidence le
significant correlati
to MISO, as measu
58
No PN PN
(n = 1:3) (Xl = 1:3)
8 1+I ( 10 0+2 :3
96+18 100+25
2 2+1 8 19+I 4
() 6_C)6 0 4+ 0J35
910+ 96 1160+ 350
;860 + 3480 22607 + 8088
3(+ 3 I 26 + 24
development of PN. There was an appar-
ent correlation between increasing severity
of PN and increased AUC, as shown in
Table VI.
TABLE VI. Ranked A UC vs development
and severity ofPNT
Rankedl AUC (fMLm) PN Gra(le
1. 2050 + 2
2. 1500 + 2
:3. 1440 + 2
4. 1240 + 1
5. 1220 + 3
6. 1200 + 3
7. 1080
8. 1050 + 3
9. 995 + 3
I(. 974
11. 972
12. 969)
1:3. 958
14. 957
15. 948
16. 936
17. 925
18. 920
19. 916
20. 898
21. 828
22. 812
23. 804
24. 793
25. 766
26. 763
+ 3
+ 2
+ 1
+ I
+ 1
DISCUSSION
-ly
__F I ) - The conclusion of most clinicians test-
2+1 21 + 1+ 9 ing MISO is that total doses of 12g/m2
or 15 g/m2 are associated with an accept-
t detailed comparison able level of neurotoxicity (Wasserman
inetic parameters for et al., 1979, 1981). However this level of
PN and those who did toxicity may be unacceptable for patients
n2 level. Although the with potentially curable, less advanced
,roup of patients with disease, especially when the beneficial
ie plasma AUC greater effects of MISO in the clinic are still
ents without PN, the unknown. Thus, the therapeutic ratio for
he standard deviation the addition of MISO to irradiation may
rnents. However, when be very specific for a given patient popula-
the 0 45 g/m2 dosage tion. Since the magnitude of the potential
ding to their AUC benefits ofMISO are unknown for patients
Mann-Whitney test with a cancer of specified site and stage,
idicates that the AUC clinicians have to decide on the incidence
tients with PN differs and severityofMISOneurotoxicityaccept-
its without PN at the able for this population, and then deter-
vel. This implies a mine the benefits, if any, for its use with
ion between exposure the established "safe" dose schedule.
ired by AUC, and the The patients chosen for the Phase I
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study reported here are specifically those
groups whom we wished to consider for
future Phase III studies.
In this study, the only toxicity of
clinical importance which developed from
MISO administration was PN. The devel-
opment of PN in patients receiving
0 45 g/m2 daily MISO (total of < 9.9 g/m2)
was the factor preventing us from adminis-
tering the planned highest MISO dose
level of 0-6 g/m2, and is obviously the
dose-limiting toxicity for MISO. Although
the incidence of PN at 0-45 g/m2 daily
was 500o (13/26) we consider that only
the 350o (9/26) with Grade 2 or 3 severity
were of clinical significance.
The detection of minimal symptoms
(Grade 1) in 4/26 suggests that if the daily
dose level were increased beyond 045 g/
m2, these patients would be at risk for
PN ofgreater severity.
Few patients in other reported Phase I
and II studies have received total MISO
doses of 6 g/m2 (Wasserman et al., 1981,
1979; Dische et al., 1978a). The absence
of PN at the 3-3 and 6 6 g/m2 dose levels
in our study suggests that for our daily
dosage schedule there is a threshold dose
below which thereareno clinical manifesta-
tions of PN. This is contrary to the con-
clusions of Wasserman et al., whose graph
of incidence of PN vs, total MISO dose
shows no threshold (Wasserman et al.,
1981). The idea of a threshold MISO dose
for PN is not meant to imply that no PN
damage occurs below that dose, but that
we have no means of detecting it.
Objective grading of the severity of
clinical symptoms is difficult because each
patient has a different tolerance for pain,
discomfort or disability. The symptom-
severity scales used in this study are
arbitrary, but the grades are defined in
some detail (Table II). The definitions
were actually made after a number of
neuropathies had developed, when it
became clear that the severity of PN,
for the patient, was based on subjective
appreciation of the amounts of discomfort
caused and how severely this impaired
functional ability. The PN severity scale
used here applies specifically to the sen-
sory neuropathy encountered at these
dose levels. It does not include motor or
CNS components.
Using this particular dose and schedule
of MISO administration, nearly half of
the patients affected (6/13) developed PN
after completion of the planned MISO
administration. We know ofnotherapeutic
measures to modify the course of MISO-
associated PN once it has occurred. The
incidence and severity of PN could only
be decreased if factors could be identified
which would predict the onset of PN
(see below). In those with onset of PN
during MISO administration (7/13) early
cessation of the drug appears to minimize
the severity and duration of symptoms.
For those 6 patients, whose MISO was
discontinued during the prescribed course
of administration, PN was of mild (Grade
1) or moderate (Grade 2) severity in 4/6,
whereas PN was severe (Grade 3) in the 4/7
patients who completed the drug course.
This study has not established that
MISO PN is always reversible. The 4
patients with PN persisting for, 2, 2, 6
and 9 months were all patients with a
severity of Grade 3. The trend for symp-
toms to peak and persist for up to 2
months and then start to improve, makes
us hope that with longer follow-ups we
will see complete resolution of PN in all
patients.
Pharmacokinetics and PN
There have been several suggestions in
the literature that the development of
MISO neurotoxicity correlates with the
total exposure to MISO (Dische et al.,
1978a). In this study, when 6/13 patients
receiving 0 45 g/m2 daily, developed PN,
we elected to double the patient entry at
this dosage, to improve confidence in the
incidence observed, and also to have
enough patients with and without PN to
statistically compare the measured phar-
macokinetic parameters for each. The
observation that there is a significant
correlation between the exposure to MISO
(as measured by the AUC) and the
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development of PN (Table VI) confirms
the observations of others, and may be
important for any future use of MISO.
A perfect correlation would have meant
all patients developing PN having AUC's
above a given level, and no patient with-
out PN with an AUC above that same
level. It is unrealistic to expect such a
perfect correlation for the AUC for MISO
alone. This would assume that only expo-
sure to MISO caused and predicted for
PN development, whereas it is known
that at least one metabolite, desmethyl-
misonidazoie, is also neurotoxic. Further-
more it is probable that there is some
variability in individual susceptibility to
MISO PN. even within the uniform type
of patient population in our study.
The fact that high AUC (> 1000 EM-h)
predicted for development of 7/9 Grade
2 and 3 PN may allow, as suggested by
Dr Dische, for some "tailoring" ofindivid-
ual daily dose to minimize the incidence
PN. Decreasing the daily dose in a
datient with a high AUC would probably
decrease the chance of PN developing,
but the decrease in toxicity might be
offsetby thedecreasedradiosensitization of
a reduced daily dose. Conversely in those
with low AUC's, the daily dose could
possibly be increased without PN increas-
ing if the AUC was monitored. This might
permit increased efficacy in those patients.
Tailoring of individual doses of MISO by
measuring AUC on the first day of
administration offers a potential method
for increasing the therapeutic ratio from
the use ofMISO with radiation.
The selection of the radiosensitizer with
the greatest chance of improving the
therapeutic ratio depends on the drugs
available for clinical use and the balance
between the potential enhancements they
can produce and their associated toxicity.
Although several investigators are cur-
rently developing drugs which may pro-
duce improvements in therapeutic ratio
(Adams et al., 1980; Brown et al., 1981) the
toxicities of these compounds in humans
are unknown. To date only metronidazole
(METRO) and MISO have been available
for large-scale clinical trials. METRO has
been discarded by most investigators,
because inferior enhancement ratios in
vitro have been observed for equivalent
drug doses. For use in patients however,
the comparison of the efficacy of MISO
and METRO must be made, not for equi-
valent doses, but for doses which produce
acceptable grades of toxicity. Our pre-
vious parallel Phase I study of METRO
and pelvic irradiation determined that
METRO can be administered in doses 2-9
times higher than MISO (1.3 g/m2 daily
METRO vs. 045g/m2MISO, Themas, etal.,
1980). At these dose levels acute gastro-
intestinal toxicity is the dose-limiting
side effect of METRO, where it is PN for
MISO. Tolerable doses of METRO pro-
duce peak plasma levels (335 + 90 ,uM)
(Thomas et al., 1980) 3 times those attain-
able with MISO (98 + 22 ,uM). In vitro and
in vivo studies suggest that the con-
centration of METRO required to pro-
duce an enhancement ratio (ER) of 1-5 is
5-10 times that of MISO, though for an
ER of 1.1 only 2-2-5 times more METRO
is necessary (Adams et al., 1976; Rauth
et al., 1978). It appears from these data
that the therapeutic advantage of MISO
over METRO is not as clear as the experi-
mental studies for equal concentrations of
both drugs would suggest.
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